http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Jun 2026 03:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html <div class="xn-content"> <p><i><span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [⁶⁸Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over <money>one billion US dollars</money> for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ma.berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b>Background: A Silent Mass Market and a Diagnostic Challenge </b></p><p>High blood pressure is one of the most common and consequential http://www.streetinsider.com/Press+Releases/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html Tue, 09 Jun 2026 03:20:00 -0400 A.14320728 O.20250741 O.61958102 PTP http://www.streetinsider.com/Press+Releases/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html <div class="xn-content"> <p><i><span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [⁶⁸Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over <money>one billion US dollars</money> for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ma.berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b>Background: A Silent Mass Market and a Diagnostic Challenge </b></p><p>High blood pressure is one of the most common and consequential http://www.streetinsider.com/Press+Releases/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html Tue, 09 Jun 2026 03:20:00 -0400 A.14320728 O.20250741 O.61958102 PTP http://www.streetinsider.com/Press+Releases/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html <div class="xn-content"> <p><i><span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [⁶⁸Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over <money>one billion US dollars</money> for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ma.berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b>Background: A Silent Mass Market and a Diagnostic Challenge </b></p><p>High blood pressure is one of the most common and consequential http://www.streetinsider.com/Press+Releases/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html Tue, 09 Jun 2026 03:20:00 -0400 A.14320728 O.20250741 O.61958102 PTP http://www.streetinsider.com/Press+Releases/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html <div class="xn-content"> <p><i><span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [⁶⁸Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over <money>one billion US dollars</money> for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ma.berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b>Background: A Silent Mass Market and a Diagnostic Challenge </b></p><p>High blood pressure is one of the most common and consequential http://www.streetinsider.com/Press+Releases/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html Tue, 09 Jun 2026 03:20:00 -0400 A.14320728 O.20250741 O.61958102 PTP http://www.streetinsider.com/PRNewswire/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html <div class="xn-content"> <p><i><span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [⁶⁸Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over <money>one billion US dollars</money> for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ma.berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b>Background: A Silent Mass Market and a Diagnostic Challenge </b></p><p>High blood pressure is one of the most common and consequential http://www.streetinsider.com/PRNewswire/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html Tue, 09 Jun 2026 03:20:00 -0400 A.14320728 O.20250741 O.61958102 PTP http://www.streetinsider.com/PRNewswire/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html <div class="xn-content"> <p><i><span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [⁶⁸Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over <money>one billion US dollars</money> for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ma.berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b>Background: A Silent Mass Market and a Diagnostic Challenge </b></p><p>High blood pressure is one of the most common and consequential http://www.streetinsider.com/PRNewswire/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html Tue, 09 Jun 2026 03:20:00 -0400 A.14320728 O.20250741 O.61958102 PTP http://www.streetinsider.com/PRNewswire/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html <div class="xn-content"> <p><i><span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [⁶⁸Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over <money>one billion US dollars</money> for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ma.berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b>Background: A Silent Mass Market and a Diagnostic Challenge </b></p><p>High blood pressure is one of the most common and consequential http://www.streetinsider.com/PRNewswire/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html Tue, 09 Jun 2026 03:20:00 -0400 A.14320728 O.20250741 O.61958102 PTP http://www.streetinsider.com/PRNewswire/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html <div class="xn-content"> <p><i><span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [⁶⁸Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over <money>one billion US dollars</money> for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.</i></p> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/us.ma.berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b>Background: A Silent Mass Market and a Diagnostic Challenge </b></p><p>High blood pressure is one of the most common and consequential http://www.streetinsider.com/PRNewswire/%5B68Ga%5DGa-PentixaFor+in+Primary+Aldosteronism%3A+Billion-Dollar+Potential+in+an+Underserved+Mass+Market/26619218.html Tue, 09 Jun 2026 03:20:00 -0400 A.14320728 O.20250741 O.61958102 PTP http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html <p>Pentixapharm Holding AG (Frankfurt: PTP) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a phase 3 clinical study of its cardiovascular diagnostic program targeting treatment-resistant hypertension with underlying primary aldosteronism.</p> <p>The IND clearance authorizes Pentixapharm to initiate its multi-center phase 3 PANDA study in the United States. The study will evaluate the company's CXCR4-targeted imaging approach for patient stratification in hypertension patients.</p> <p>The phase 3 study design was developed based on FDA guidance received during a Type B pre-IND meeting, which provided direction on statistical and methodological aspects and evidence requirements for a potential http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html Tue, 09 Jun 2026 03:11:22 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html <p>Pentixapharm Holding AG (Frankfurt: PTP) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a phase 3 clinical study of its cardiovascular diagnostic program targeting treatment-resistant hypertension with underlying primary aldosteronism.</p> <p>The IND clearance authorizes Pentixapharm to initiate its multi-center phase 3 PANDA study in the United States. The study will evaluate the company's CXCR4-targeted imaging approach for patient stratification in hypertension patients.</p> <p>The phase 3 study design was developed based on FDA guidance received during a Type B pre-IND meeting, which provided direction on statistical and methodological aspects and evidence requirements for a potential http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html Tue, 09 Jun 2026 03:11:22 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html <p>Pentixapharm Holding AG (Frankfurt: PTP) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a phase 3 clinical study of its cardiovascular diagnostic program targeting treatment-resistant hypertension with underlying primary aldosteronism.</p> <p>The IND clearance authorizes Pentixapharm to initiate its multi-center phase 3 PANDA study in the United States. The study will evaluate the company's CXCR4-targeted imaging approach for patient stratification in hypertension patients.</p> <p>The phase 3 study design was developed based on FDA guidance received during a Type B pre-IND meeting, which provided direction on statistical and methodological aspects and evidence requirements for a potential http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html Tue, 09 Jun 2026 03:11:22 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html <p>Pentixapharm Holding AG (Frankfurt: PTP) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a phase 3 clinical study of its cardiovascular diagnostic program targeting treatment-resistant hypertension with underlying primary aldosteronism.</p> <p>The IND clearance authorizes Pentixapharm to initiate its multi-center phase 3 PANDA study in the United States. The study will evaluate the company's CXCR4-targeted imaging approach for patient stratification in hypertension patients.</p> <p>The phase 3 study design was developed based on FDA guidance received during a Type B pre-IND meeting, which provided direction on statistical and methodological aspects and evidence requirements for a potential http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html Tue, 09 Jun 2026 03:11:22 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html <p>Pentixapharm Holding AG (Frankfurt: PTP) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a phase 3 clinical study of its cardiovascular diagnostic program targeting treatment-resistant hypertension with underlying primary aldosteronism.</p> <p>The IND clearance authorizes Pentixapharm to initiate its multi-center phase 3 PANDA study in the United States. The study will evaluate the company's CXCR4-targeted imaging approach for patient stratification in hypertension patients.</p> <p>The phase 3 study design was developed based on FDA guidance received during a Type B pre-IND meeting, which provided direction on statistical and methodological aspects and evidence requirements for a potential http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html Tue, 09 Jun 2026 03:11:22 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html <p>Pentixapharm Holding AG (Frankfurt: PTP) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a phase 3 clinical study of its cardiovascular diagnostic program targeting treatment-resistant hypertension with underlying primary aldosteronism.</p> <p>The IND clearance authorizes Pentixapharm to initiate its multi-center phase 3 PANDA study in the United States. The study will evaluate the company's CXCR4-targeted imaging approach for patient stratification in hypertension patients.</p> <p>The phase 3 study design was developed based on FDA guidance received during a Type B pre-IND meeting, which provided direction on statistical and methodological aspects and evidence requirements for a potential http://www.streetinsider.com/FDA/Pentixapharm+receives+FDA+clearance+for+phase+3+hypertension+study/26619212.html Tue, 09 Jun 2026 03:11:22 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/Press+Releases/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Frankfurt:PTP" idsrc="xmltag.org" >Pentixapharm Holding AG</span> (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.</p> <p>With the IND now in effect, Pentixapharm is authorized to initiate its <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-focused, multi-center Phase 3 <span>PANDA</span> clinical study evaluating its novel imaging approach for patient stratification in hypertension, addressing a significant and underdiagnosed segment http://www.streetinsider.com/PRNewswire/Pentixapharm+Announces+FDA+Clearance+of+IND+for+Phase+3+PANDA+Study+of+First-in-Class+Cardiovascular+Diagnostic+Program/26619211.html Tue, 09 Jun 2026 03:10:00 -0400 A.06822034 A.50203974 O.00028300 O.20026344 O.61958102 PTP